NASDAQ: COO · Medical Instruments & Supplies
Cooper Companies (COO) fair value: undervalued or overvalued?
As of 27 Sep 2026, Faircurve's model values Cooper Companies (COO) at $56.76 a share. The stock last closed at $56.91, which puts the model's fair value 0.3% below the price. On the model's bands that reads as Fairly valued.
Revalued . Price is the close of 2 Oct 2026. The Cooper Companies, Inc.
Faircurve Insights · 27 Sep 2026
The Cooper Companies, Inc. (COO) is a global medical device firm. It develops, produces, and distributes products through CooperVision and CooperSurgical, with CooperVision specializing in contact lenses.
Faircurve's model found a fair value of $56.76 a share on 27 Sep 2026. This is the midpoint of 2,000 simulations. The previous run, on 19 Sep 2026, gave $57.26, and the fair value moved -0.9%. The calibrated range is $47.62 to $69.21, built from the fair value. This range has held the price 60% of the time at this horizon. The evidence grade is High.
The overall quality score is 39 out of 100 against comparable companies. The model compares The Cooper Companies with Repligen Corporation (RGEN), Avantor, Inc. (AVTR), Baxter International Inc. (BAX), AptarGroup, Inc. (ATR), Solventum Corporation (SOLV), Merit Medical Systems, Inc. (MMSI), and West Pharmaceutical Services, Inc. (WST). Moves around the last 8 earnings reports had a median size of 9.4%.
Written from the figures on this page for the 27 Sep 2026 valuation and checked by rule before publishing: every number is one printed here, no forecast, no instruction. The price, the gap and the verdict are the page's own and change daily. Not a recommendation.
What price range does the model give COO?
The calibrated range for COO over 63 trading days is $47.62 to $69.21. There is no live options data for this stock, so the range is built from the fair value and calibrated weekly against realised prices (n = 4,327 past valuations, refreshed 26 Sep 2026). Ranges built this way held the price 60% of the time at this horizon.
The model's own simulated range, from the 20th to the 80th percentile of its runs, is $46.13 to $68.42. In 54% of the simulations the fair value came out above the price the model ran on.
How does COO score on business quality?
Cooper Companies's overall quality score is 39 out of 100. Each factor below is a score against comparable companies, not a percentile of the metric beside it.
| Factor | Score (0 to 100) | Headline measure | Peer median |
|---|---|---|---|
| ProfitabilityReturn on invested capital against the peer group, with a bonus for an improving trend. | 34 | 5.1%ROIC | 6.8% |
| Earnings qualityHow much of reported profit is cash: free cash flow to net income, and the accrual ratio (the share of earnings that is not cash). | 41 | 1.19xFCF / net income | 1.36x |
| Growth qualityTrailing revenue growth, forward growth from consensus, and the direction of analyst estimate revisions. | 42 | 5.1%Revenue growth, trailing | 1.5% |
| Capital disciplineReinvestment efficiency (capital spending per unit of revenue) and net buybacks. | 29 | 0.5%Net buybacks / market value | 0.2% |
| Balance sheetNet debt to EBITDA and interest coverage. | 38 | 2.63xNet debt / EBITDA | 1.63x |
| StabilityDownside volatility of the EBITDA margin over the last five years. | 57 | 0.9 ptsEBITDA margin downside volatility, 5y | 1.6 pts |
How does COO compare with similar companies?
The companies in medical instruments & supplies closest to Cooper Companies in market value, each on the same model and the same date.
| Company | Last close | Model fair value | Gap | Model verdict |
|---|---|---|---|---|
| RGEN Repligen Corporation | $181.70 | $150.23 | -17.3% | Overvalued |
| AVTR Avantor, Inc. | $15.34 | $18.04 | +17.6% | Undervalued |
| BAX Baxter International Inc. | $23.49 | $23.91 | +1.8% | Fairly valued |
| ATR AptarGroup, Inc. | $119.91 | $120.42 | +0.4% | Fairly valued |
| SOLV Solventum Corporation | $87.85 | $97.08 | +10.5% | Fairly valued |
| TFX Teleflex Incorporated | $124.12 | $125.37 | +1.0% | Low evidence grade |
| MMSI Merit Medical Systems, Inc. | $85.37 | $88.67 | +3.9% | Fairly valued |
| WST West Pharmaceutical Services, Inc. | $364.98 | $363.43 | -0.4% | Fairly valued |
All medical instruments & supplies stocks ranked by gap to fair value
When does COO report earnings, and how has the stock reacted?
Cooper Companies's next earnings report is scheduled for 3 Dec 2026. Companies can move their dates.
How COO moved around its last 8 earnings reports
Each move runs from the last close before the report to the first close after it, so it covers companies that report before the open and after the close. The median size across these 8 reports, ignoring direction, was 9.4%.
| Report date | Two session move |
|---|---|
| 9 Sep 2026 | -20.0% |
| 4 Jun 2026 | +11.6% |
| 5 Mar 2026 | -6.6% |
| 4 Dec 2025 | +7.1% |
| 27 Aug 2025 | -12.3% |
| 29 May 2025 | -14.8% |
| 6 Mar 2025 | -6.9% |
| 5 Dec 2024 | -6.0% |
Cooper Companies at a glance
The Cooper Companies, Inc. (COO) operates as a global medical device firm, primarily focused on developing, producing, and distributing products through two distinct business units: CooperVision and CooperSurgical. CooperVision specializes in contact lenses.
- Market value
- $10.8B
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies
- Revenue expected, next twelve months
- $4.4B
- Consensus revenue growth, next fiscal year
- +3.6%
- Analysts with estimates
- 11
- Beta to the US market
- 0.41
- First valued by Faircurve
- 1 May 2026
How the fair value is worked out: the model prices Cooper Companies on the value of the whole business, debt included, against the operating profit analysts expect next year (forward EV/EBITDA), runs 2,000 simulations across its inputs and takes the midpoint. The full method is documented here.
What changed in the latest valuation?
On 19 Sep 2026 the model's fair value for COO was $57.26. As of 27 Sep 2026 it is $56.76, a change of -0.9%. The model revalues every stock it covers each week, and again after an earnings report.
Questions about Cooper Companies's valuation
Is Cooper Companies stock undervalued or overvalued?
On Faircurve's model, COO reads as Fairly valued as of 27 Sep 2026. The model's fair value is $56.76 a share against a last close of $56.91, a gap of -0.3%.
What is COO's fair value?
$56.76 a share as of 27 Sep 2026, the midpoint of 2,000 simulations. The model's own 20th to 80th percentile range is $46.13 to $68.42.
What price range does the model give COO?
$47.62 to $69.21 over 63 trading days. Ranges built this way held the price 60% of the time across 4,327 past valuations, refreshed 26 Sep 2026.
When does Cooper Companies report earnings next?
The next report is scheduled for 3 Dec 2026. Companies can move their dates.
How much has COO moved on past earnings reports?
Across its last 8 reports the median two session move was 9.4%, ignoring direction. The largest was -20.0% around the report of 9 Sep 2026.
How confident is the model in this valuation?
The model's evidence grade for COO is high. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It is not a probability that the fair value is right, or that the price reaches it.